TLDR Tofacitinib helped a teenager with severe hair loss grow hair back, but more research is needed.
The document described a case study where a 16-year-old male with alopecia universalis (AU), who had not responded to previous treatments, experienced significant hair regrowth after five months of treatment with tofacitinib, a JAK1/3 inhibitor. The patient took 5 mg of tofacitinib orally twice daily and saw hair regrowth on the scalp, eyebrows, arms, and legs, with increased appetite and weight gain as the only side effects. Blood tests remained normal throughout the treatment. This case suggests that JAK inhibitors could be a promising treatment for pediatric AU, but further research is necessary to confirm their efficacy and establish the best treatment protocols.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
24 citations
,
January 2018 in “International Journal of Trichology” Tofacitinib helped regrow hair in patients with alopecia, with few side effects.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
